The IP Gauntlet: Seer's Legal Victories Shape the Proteomics Frontier

REDWOOD CITY, CA – July 01, 2026

In the hyper-competitive world of biotechnology, where a single molecule can be worth billions, intellectual property is more than a legal asset; it is the kingdom and the key. This principle was on full display last week as Seer, Inc., a firm positioning itself at the vanguard of proteomics, announced two decisive victories that reinforce its technological moat. The moves—a successful patent defense in Europe and the launch of a U.S. trade investigation against a competitor—are not merely procedural wins. They represent a calculated, aggressive strategy to define the rules of engagement in one of the most promising fields of modern medicine.

The Technology at the Heart of the Dispute

To understand the significance of Seer's legal maneuvers, one must first grasp the challenge it aims to solve. Proteomics, the large-scale study of proteins, holds the key to unlocking the earliest signs of disease and developing hyper-personalized therapies. However, the human proteome is notoriously complex. In a single drop of blood, a few high-abundance proteins like albumin act like a blinding fog, obscuring thousands of low-abundance proteins that often serve as critical biomarkers for conditions like cancer or neurological disorders. This is known as the “dynamic range problem,” and it has long been the primary bottleneck for the field.

Seer's breakthrough, protected by a growing fortress of patents, is its Proteograph® Product Suite. The technology hinges on proprietary engineered nanoparticles. When introduced to a biological sample, these particles form a “protein corona,” a unique and reproducible coating of proteins from the sample. By designing nanoparticles with specific physicochemical properties, Seer can selectively capture a vast diversity of proteins, effectively dimming the glare of high-abundance ones to reveal the faint signals of their low-abundance counterparts. It is this particle-based enrichment method that forms the core of Seer’s value proposition and the subject of its fierce legal defense.

The European Patent Office (EPO) recently affirmed the novelty of this approach. On June 25, it upheld Seer’s European Patent No. EP4056263, which broadly covers this foundational technology. The decision, which followed an opposition from an unnamed party seeking to revoke the patent, sends a clear signal about the strength and defensibility of Seer’s innovation in a key global market. The patent is formally owned by The Brigham and Women's Hospital and exclusively licensed to Seer, a common arrangement that bridges academic discovery with commercial execution.

A Two-Front War: Europe and the U.S. ITC

While the EPO decision secured its flank in Europe, Seer simultaneously opened a new front in its home market. On June 29, the U.S. International Trade Commission (ITC), a powerful quasi-judicial body, instituted an investigation into Nanomics Biotechnology Co., Ltd. Seer alleges that the China-based competitor, which also has a U.S. presence, is infringing on five of its U.S. patents with its Proteonano kits and workstations.

The choice of venue is strategically critical. The ITC operates under Section 337 of the Tariff Act of 1930 and specializes in cases involving unfair trade practices related to imported goods. It is known for its blistering pace, with investigations typically reaching a final determination in just 12 to 18 months—far faster than traditional federal court litigation. More importantly, its primary remedy is the exclusion order, a powerful injunction that directs U.S. Customs and Border Protection to bar infringing products from entering the country. Seer is seeking precisely this, aiming to block Nanomics' products at the border.

Nanomics, founded in 2021, represents the new wave of competitors vying for a piece of the proteomics pie. Its technology, which also aims to enrich low-abundant proteins for biomarker discovery, places it in direct competition with Seer. The ITC’s decision to institute the investigation, despite Nanomics’ request to decline it, suggests Seer’s complaint has met the commission’s rigorous standards. This action runs parallel to a patent infringement suit Seer filed in federal court, a common two-pronged strategy that allows a company to seek both an import ban from the ITC and monetary damages from the court system.

The High-Stakes Proteomics Market

These legal battles are not taking place in a vacuum. They are skirmishes in a war for dominance over a market experiencing explosive growth. Valued at over $40 billion in 2026, the global proteomics market is projected by analysts to surge past $100 billion by the early 2030s, fueled by its expanding role in drug discovery, clinical diagnostics, and the quest for precision medicine. As the technology matures, it is moving from the exclusive domain of academic research into mainstream clinical applications, dramatically raising the commercial stakes.

For companies like Seer, establishing and defending foundational IP is paramount. “We pioneered this field and built the foundational intellectual property that underpins it,” said Omid Farokhzad, Chair and Chief Executive Officer of Seer, in a recent statement. “These actions underscore the strength of our IP portfolio and make clear that we will vigorously defend our innovations.”

This sentiment is echoed by industry analysts, who note that in capital-intensive fields like biotech, robust patent protection is essential to justify the massive upfront investment in research and development. A strong IP position not only protects market share but also enhances a company’s valuation and attractiveness for partnerships and acquisitions.

The Strategic Blueprint for Biotech Dominance

Seer's strategy appears to be a classic page from the biotech playbook: build a disruptive technology, fortify it with a wall of patents, and then aggressively defend that wall to secure a long-term competitive advantage. While currently unprofitable and burning cash to fund R&D—a common status for growth-stage biotech firms—Seer maintains a strong balance sheet with more cash than debt. This financial footing gives it the necessary war chest to sustain costly, multi-front legal campaigns that might exhaust less-capitalized rivals.

By successfully defending its patent in Europe and launching a formidable ITC challenge in the U.S., Seer is doing more than just protecting its revenue streams. It is shaping the competitive landscape for years to come. A victory at the ITC would not only neutralize a direct competitor in the lucrative U.S. market but also serve as a powerful deterrent to any other company considering a similar technological path. This forces the competition into a difficult position: either challenge Seer’s patents and risk a costly legal defeat, or invest in developing alternative technologies that do not infringe on its IP. Either outcome solidifies Seer's position as a central gatekeeper of next-generation proteomics technology.